<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459977</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0209</org_study_id>
    <nct_id>NCT02459977</nct_id>
  </id_info>
  <brief_title>The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Basiliximab has been a routine induction therapeutic agent even for well-matched living
      kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is
      a different drug from cyclosporine, the investigators study the usefulness of
      tacrolimus-based immunosuppression without basiliximab in well matched living KT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators omit basiliximab induction therapy in patients who underwent one to
      three-HLA mismatched living donor renal transplantation. Participants should receive ABO
      compatible and T-flow negative transplants. The investigators compare the results of
      intervention group with conventionally treated control group (age and sex matched patient who
      underwent one to three-HLA mismatched living donor renal transplants with basiliximab
      induction therapy).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of rejection</measure>
    <time_frame>within 3 years</time_frame>
    <description>The investigators measures incidence of rejection by serum creatinine, urinalysis and kidney allograft biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>postoperative 6 month, 1 year, 1.5 year, 2 years and 3 years</time_frame>
    <description>The investigators measures incidence of infection such as CMV, BKV infection, pneumonia, urinary tract infection and other infections.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>No basiliximab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basilixiab group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>Basiliximab induction therapy</description>
    <arm_group_label>Basilixiab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No basiliximab</intervention_name>
    <description>No basiliximab induction therapy</description>
    <arm_group_label>No basiliximab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney transplantation</intervention_name>
    <description>kidney transplantation</description>
    <arm_group_label>No basiliximab group</arm_group_label>
    <arm_group_label>Basilixiab group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ABO compatible and T-flow negative transplants

          -  Living kidney transplantation

          -  Tacrolimus based immunosuppression

        Exclusion Criteria:

          -  Multiorgan transplantation

          -  Zero-mismatch transplantation (we use cyclosporine instead of FK506)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su-Kil Park, M.D, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chung Hee Baek, M.D.</last_name>
    <phone>82-2-3010-1481</phone>
    <email>bch393@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Su-Kil Park, M.D, PhD</last_name>
    <phone>82-2-3010-3263</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su-Kil Park, M.D., PhD</last_name>
      <phone>82-2-3010-3263</phone>
      <email>skpark@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Chung Hee Baek, M.D.</last_name>
      <phone>82-2-3010-1481</phone>
      <email>bch393@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Su-Kil Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

